In patients with EGFR-mutated NSCLC, EGFR-TKIs, the first-line agent, represented by gefitinib obtain obvious clinical responsiveness and greatly prolong the survival time of patients (Lynch et al. 2004; Prabhu and Devaraj 2017). This evidence concerns the gene EGFR and non-small cell lung carcinoma.